Does high sensitive CRP improve cardiovascular risk prediction in metabolic syndrome among the aged?

作者：Salminen Marika^*; Kuoppamaki Marikka; Vahlberg Tero; Raiha Ismo; Irjala Kerttu; Kivela Sirkka Liisa

来源：Scandinavian Cardiovascular Journal, 2013, 47(4): 210-216.

DOI：10.3109/14017431.2013.798427

• aged
• cardiovascular
• high-sensitivity C-reactive protein
• metabolic syndrome
• mortality

Objectives. To analyze whether an elevated level of high hsCRP has an additive effect on metabolic syndrome (MetS) in predicting future cardiovascular events (CVEs) as well as on all-cause mortality among the aged subjects. Design. A prospective, population-based study with a 9-year follow-up. The study population consisted of persons aged 64 and above in 1998-99 without vascular disease and CRP less than 10 mg/l at baseline (n = 733). Adjusted hazard ratios (HRs) and their 95% confidence intervals (CIs) for CVEs and all-cause mortality predicted by baseline MetS (defined by both International Diabetes Federation (IDF) and World Health Organization (WHO)) and hsCRP-level were estimated. Results. During the 9-year follow-up, a total of 142 CVEs and 206 deaths occurred. After multivariable adjustment, no significant interactions were found between hsCRP and MetS in CVEs (IDF: p = 0.828; WHO: p = 0.572) or in all-cause mortality (IDF: p = 0.113; WHO: p = 0.374). HsCRP was not associated with the occurrence of CVEs (IDF: HR = 1.10, 95% CI = 0.92-1.32, p = 0.281; WHO: HR = 1.10, 95% CI = 0.93-1.32, p = 0.247) or with all-cause mortality (IDF: HR = 1.12, 95% CI = 0.97-1.29, p = 0.134;WHO: HR = 1.11, 95% CI = 0.96-1.28, p = 0.146). Conclusions. It seems that hsCRP does not give any extra value in evaluation of CVE risk or all-cause mortality of older subjects with MetS.

• 出版日期2013-8